# Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer

> **NCT00509665** · PHASE2 · COMPLETED · sponsor: **Medical University of South Carolina** · enrollment: 18 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** doxorubicin hydrochloride
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00509665
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509665, "Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00509665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*